COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits. All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Mitul Gandhi, MD

VCS Physicians

Mitul Gandhi, MD Headshot

I am mindful of how life altering a diagnosis of cancer can be, not just for the patient, but all the loved ones in their life as well. Patients and families rightly deserve, and will always get the very best of us in intelligence and compassion, along with access to state of the art treatment which is continually improving long-term outcomes.

Work and Credentials:

Primary Location

Gainesville Office

Position

Medical Oncologist

Board Certification

Medical Oncology, Hematology, and Internal Medicine

Fellowship

Northwestern University Feinberg School of Medicine, Medical Oncology and Hematology

Internship

University of Michigan Health System

Residency

University of Michigan Health System

Medical School

Rutgers Robert Wood Johnson Medical School

College

Rutgers University

Mitul Gandhi, M.D. attended Rutgers University where he graduated Magna Cum Laude with a Bachelor of Arts in Molecular Biology and Biochemistry. He earned his medical degree from Rutgers Robert Wood Johnson Medical School where he received the Robert Wood Johnson Foundation Research Award among other honors. Dr. Gandhi then completed his residency and internship in Internal Medicine at University of Michigan Health System.

Dr. Gandhi joins Virginia Cancer Specialists after serving as Chief Fellow in the Medical Oncology and Hematology Fellowship program at Northwestern University Feinberg School of Medicine. During his time at Northwestern, Dr. Gandhi actively participated in clinical research, with a focus in high risk lymphoma. He has presented at major national meetings, won the American Society of Hematology’s Abstract Achievement Award in 2013, and has several publications including a recent article in Blood on double hit lymphomas. Dr. Gandhi is currently an Associate Member of both the American Society of Hematology and the American Society of Clinical Oncology.

In his spare time, Dr. Gandhi enjoys traveling with his wife, reading and writing, and spending time with family and friends.


thumbnail of TopDocs Washingtonian 2021




Physician Video:

Physician Reviews:

Healthgrades User
Healthgrades User
2021-07-19 00:00:00
Healthgrades User

Wait time was minimal. Pleasant staff. Dr. Gandhi was great!

Healthgrades User
Healthgrades User
2021-05-24 00:00:00
Healthgrades User

Professional, efficient and caring. He is a terrific medical resource.

Charles Ruby
Charles Ruby
2021-05-21 00:00:00
Charles Ruby

Dr. Gandhi has done a wonderful job in deleting my tumor and continuing to check that it stays gone.

Healthgrades User
Healthgrades User
2021-04-26 00:00:00
Healthgrades User

I highly recommend Dr. Gandhi and his entire staff. I've been a patient of Dr. Gandhi's for over 5 years. They have always been very professional, considerate and knowledgeable.

Julie Henry
Julie Henry
2021-04-22 00:00:00
Julie Henry

Dr Gandhi truly cares about his patients. I love that Dr Gandhi is into research and latest treatments.

Healthgrades User
Healthgrades User
2021-04-21 00:00:00
Healthgrades User

I always receive professional, courteous and friendly treatment by Dr. Gandhi and the other VCS medical personnel. I highly recommend them.

June Albrite
June Albrite
2021-03-04 00:00:00
June Albrite

SAW NURSE PRACTITIONER

Practice Blog

October 11, 2021

Virginia Cancer Specialists Participating in National Pilot Project to Increase Diversity in Cancer Treatment Trials

Read More
October 4, 2021

Virginia Cancer Specialists Opens New Office in Fauquier -- Expanding Access to Cancer Care, Research and Clinical Trials

Read More

Physician Publications

December 6, 2020

Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma

Read More
December 5, 2020

NHL Patients and Nurses in the US Prefer Subcutaneous Rituximab Injection Versus Intravenous Rituximab Infusion: A Real-World Study

Read More
February 15, 2016

Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.

Read More

More Publications by Mitul Gandhi, MD

May 1, 2014

Pancreatitis in patients treated with Brentuximab Vedotin: A previously unrecognized serious adverse

Read More
April 22, 2014

Predicting benefit from imatinib. Are we close? Leukemia and Lymphoma.

Read More
February 13, 2014

Targeted treatment of head and neck squamous cell carcinoma: potential of lapatinib.

Read More
November 15, 2013

Impact of Induction Regimen and Consolidative Stem Cell Transplantation in Double Hit Lymphoma (DHL)

Read More
January 7, 2013

Association of implantable defibrillator therapy risk with body mass index in systolic heart failure

Read More
January 1, 2013

Brentuximab Vedotin in Patients with Relapsed HIV-Related Lymphoma

Read More

Clinical Trials (20)

Clinical Trial USOR 18126

A Phase 1 Study of SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)


Clinical Trial ADCT-402-105

A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma


Clinical Trial USOR 20285

A Phase 2 Trial of Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Combination with Selinexor For Patients with Newly Diagnosed Multiple Myeloma


Clinical Trial M20-178

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis


Clinical Trial 20177

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis


Clinical Trial SLSG18-301

A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

All Clinical Trials for Mitul Gandhi, MD

Clinical Trial USOR 18126

A Phase 1 Study of SEA-BCMA in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT03582033

ClinicalTrials.gov Link:

Click Here


Clinical Trial ADCT-402-105

A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04970901

ClinicalTrials.gov Link:

Click Here


Clinical Trial USOR 20285

A Phase 2 Trial of Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Combination with Selinexor For Patients with Newly Diagnosed Multiple Myeloma

ClinicalTrials.gov ID:

NCT04782687

ClinicalTrials.gov Link:

Click Here


Clinical Trial M20-178

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis

ClinicalTrials.gov ID:

NCT04468984

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20177

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis

ClinicalTrials.gov ID:

NCT04472598

ClinicalTrials.gov Link:

Click Here


Clinical Trial SLSG18-301

A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator’s Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

ClinicalTrials.gov ID:

NCT04229979

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20178

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myeldysplastic Syndrome

ClinicalTrials.gov ID:

NCT04401748

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20287

A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients with Relapsed/Refractory AML

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04358393

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20343

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator’s Choice of Idelalisib Plus Rituxan or Bendamustine Plus Rituxan in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

ClinicalTrials.gov ID:

NCT04666038

ClinicalTrials.gov Link:

Click Here


Clinical Trial ADCT-402-311

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

 

ClinicalTrials.gov ID:

NCT04384484

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20133

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-Intermediate and High-Risk Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

ClinicalTrials.gov ID:

NCT04824092

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20336

A Phase 3, Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma

ClinicalTrials.gov ID:

NCT04662255

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19062

Phase 3 Double-Blind, Active Controlled, 3-Stage Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma.

ClinicalTrials.gov ID:

NCT04224493

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20298

Phase 2 Study of VS-6766 (Dual RAK/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

ClinicalTrials.gov ID:

NCT04625270

ClinicalTrials.gov Link:

Click Here


Clinical Trial D967JC00001

A Phase 1b/2 Multicenter, Open-Label, Dose Finding Study to Explore Safety, Efficacy, and Activity of Trastuzumab Deruxtecan (T-Dxd) in Combination with Other Anti-Cancer Agents in Patients with HER2+ Metastatic Breast Cancer

Locations:

Fairfax Office

ClinicalTrials.gov ID:

NCT04538742

ClinicalTrials.gov Link:

Click Here


Clinical Trial 20210

Breast Cancer Index Registry Study

ClinicalTrials.gov ID:

NCT04875351

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18263

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

ClinicalTrials.gov ID:

NCT03206918

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19247

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

ClinicalTrials.gov ID:

NCT03901963

ClinicalTrials.gov Link:

Click Here


Clinical Trial 18013

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects .  Ph2 A+AVD +G-CSF or AOAD in CHL

ClinicalTrials.gov ID:

NCT03646123

ClinicalTrials.gov Link:

Click Here


Clinical Trial 19205

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

ClinicalTrials.gov ID:

NCT03801525

ClinicalTrials.gov Link:

Click Here